Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21867124 | 0.86 | HRH3 (0.36) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL4668405 | 0.79 | HRH3 (0.60) | HRH3SMN1; SMN2ALDH1A1TSHRCNR1 | |
| SCHEMBL3857098 | 0.78 | CHRNB2 (0.45) | HRH3ALDH1A1TSHRHPGDCNR1 | |
| SCHEMBL3857094 | 0.78 | CHRNB2 (0.45) | HRH3ALDH1A1TSHRHPGDCNR1 | |
| SCHEMBL3863795 | 0.78 | HPGD (0.58) | HRH3SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3867174 | 0.78 | HPGD (0.58) | HRH3SMN1; SMN2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL3860651 | 0.77 | CHRNB2 (0.44) | HRH3ALDH1A1TSHRCNR1LMNA | |
| Hydrochloric Acid SCHEMBL3860655 | 0.77 | CHRNB2 (0.44) | HRH3ALDH1A1TSHRCNR1LMNA | |
| SCHEMBL5195512 | 0.76 | CHRNB2 (0.36) | HRH3 | |
| SCHEMBL4668416 | 0.76 | CHRNB2 (0.36) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802307-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| EP-1802307-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040192-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | HRH4, HRH3, HRH2 | HRH3 2/4885SMN1; SMN2 3501/4885XPNPEP2 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.